Revenue: As of FY2026 Q2, the actual value is USD 12.05 M, beating the estimate of USD 11.62 M.

EPS: As of FY2026 Q2, the actual value is USD 0.01.

EBIT: As of FY2026 Q2, the actual value is USD 198.38 K.

Second Quarter 2026 Financial Highlights

KORU Medical Systems, Inc. reported net revenues of $12.0 million for the second quarter of 2026, marking an 18% increase over the prior year period. Gross profit grew 20% year-over-year to $7.8 million, with a gross margin of 65.1%. Net income improved by 222% over the prior year period, reaching $0.25 million. Adjusted EBITDA for the quarter was $0.9 million, an increase from $0.3 million in the prior year period. Cash and cash equivalents stood at $8.3 million as of June 30, 2026, reflecting a cash usage of $0.5 million during the second quarter of 2026.

Segment Revenue (Three Months Ended June 30, 2026 vs. 2025)

Domestic Core revenues were $7,979,558, an increase of 12.4% from $7,097,285 in the prior year period. International Core revenues grew by 59.1% to $3,469,558, up from $2,180,111. Total Core revenues reached $11,449,116, a 23.4% increase from $9,277,396. Pharma Services and Clinical Trials net revenues decreased by 35.0% to $596,304, down from $917,404.

Operational Metrics (Three Months Ended June 30, 2026 vs. 2025)

Gross profit increased by $1.4 million, or 21.2%, to $7,846,208 compared to $6,475,769 in the prior year period. Gross margin increased to 65.1% from 63.5% in the prior year period, primarily due to lower manufacturing costs and higher average selling prices. Total operating expenses increased by $0.4 million, or 6.3%, to $7,219,217. Net operating income was $626,991, an improvement from a net operating loss of - $312,655 in the prior year period. Net income was $252,449, compared to a net loss of - $206,867 in the prior year period.

Cash Flow (Six Months Ended June 30, 2026 vs. 2025)

Net cash flows from operating activities were $230,776, a significant improvement from net cash used in operating activities of - $697,807 in the prior year period.

Unique Metrics

KORU Medical Systems, Inc. acquired a connected monitoring technology asset, representing a strategic investment to potentially enhance and differentiate its platform through real-time data insights into patient usage. The company is strategically shifting its U.S. oncology market entry to focus on alternative higher volume molecules and has withdrawn its 510(k) application for the FreedomEDGE® with Phesgo® in the U.S. Additionally, a multi-year supply agreement was entered into to support operational strategy, product assurance, and long-term gross margin expansion.

Outlook / Guidance

KORU Medical Systems, Inc. refined its full-year 2026 net revenues guidance to be between $47.5 million and $48.5 million, representing 15% to 18% growth, and raised its gross margin guidance to between 62% and 64%. The company reiterated expectations for positive adjusted EBITDA. The year-end cash balance is updated to be greater than $7.5 million, accounting for the technology acquisition.